Transforming science into strategy for successful drug development
We provide expert scientific and regulatory guidance in DMPK, toxicology, and non-clinical safety. We support biotech and pharmaceutical companies from early discovery to first-in-human, clinical development and regulatory submission.
Science-driven. Strategy-focused. Client-centred.
At MS Pharma Consulting, we help our clients to overcome the scientific and regulatory challenges that often cause delays in drug development.
We translate complex DMPK and toxicology data into clear discovery or development strategies that support decision-making, reduce risk and accelerate timelines.
Operating with the agility of a consulting firm and the expertise of a senior pharmaceutical partner, we deliver tailored support for rapid problem-solving or full programme strategy.
Integrated consultancy in DMPK, toxicology and non-clinical safety
Strategic and business support
Independent scientific insight for investors, biotech leadership and business development teams.
- Due diligence
- Portfolio and asset evaluation
- Risk assessment
- EU/US development strategy alignment
Pharmacokinetics, drug metabolism and toxicology
We support programmes from hit identification through to clinical development and registration.
- ADME screening cascades
- Candidate selection
- IND-enabling packages
- CRO selection and study oversight
Regulatory interactions
Strategic and hands-on regulatory support aligned with EMA and FDA expectations.
- Clinical pharmacokinetics strategy
- Toxicology and safety pharmacology
- Dose justification
- Briefing documents and agency support
Clear strategy for complex development challenges
ADME screening and lead optimisation
Design and optimisation of ADME screening cascades from hit-to-lead to candidate selection.
IND-enabling programmes
Strategic support for non-clinical packages required to progress towards first-in-human studies.
Development strategy
Integrated scientific support to select the right candidate and build a robust development strategy.
Regulatory documents and agency interactions
Preparation and scientific support for regulatory documentation and interactions with agencies.
Due diligence and second opinions
Independent scientific review for investors, biotech leadership and business development teams.
Risk assessment and mitigation
Early identification of potential DMPK, toxicology and regulatory risks across discovery and development.
Integrated, pragmatic and data-driven support
Miquel Salva
Miquel Salva is a recognised expert in ADME/DMPK and toxicology with over 30 years experience in drug discovery and development.
He led the DMPK and toxicology functions at Almirall, and served as Executive Director of DMPK and Safety at Syngene International.
His work has contributed to the development and approval of several marketed drugs, including Almotriptan, Aclidinium bromide, Linaclotide, Dimethyl fumarate, Tildrakizumab and Tirbanibulin.
Contact Miquel Salva